ArticleAdvances in therapy2023

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.

Hidetoshi Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.